Regeneron Pharmaceuticals
REGN
549 hedge funds and large institutions have $25.9B invested in Regeneron Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 193 increasing their positions, 223 reducing their positions, and 91 closing their positions.
5% less funds holding
Funds holding: 575 → 549 (-26)
13% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 223
15% less call options, than puts
Call options by funds: $493M | Put options by funds: $583M
24% less first-time investments, than exits
New positions opened: 69 | Existing positions closed: 91
38% less capital invested
Capital invested by funds: $42B → $25.9B (-$16.1B)
52% less funds holding in top 10
Funds holding in top 10: 27 → 13 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
+$2.91B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$988M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$588M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$86.6M |
| 5 |
Two Sigma Advisers
New York
|
+$61.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$490M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$296M |
| 3 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$151M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$145M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
-$128M |
REGN Hedge Fund Activity: Q1 2016 in Review
549 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2016, worth a combined $25.9B — down 38% from $42B a quarter earlier.
Sellers outnumbered buyers: 91 funds closed out of REGN and 69 opened new positions — a net loss of 22 holders — while 223 trimmed existing stakes and 193 added.
The largest buyer was Royal London Asset Management, adding an estimated $2.91B. The largest seller was JP Morgan Chase, cutting an estimated $490M.
- 549 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2016, down from 575 in Q4 2015.
- Funds reported $25.9B of Regeneron Pharmaceuticals stock for Q1 2016, down 38% quarter-over-quarter.
- 69 funds opened new Regeneron Pharmaceuticals positions in Q1 2016 and 91 closed out, a net change of -22 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2016 was Royal London Asset Management, an estimated $2.91B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2016 was JP Morgan Chase, an estimated $490M sold.
Based on aggregated 13F filings for Q1 2016.